Minnesota Assessment of Pharmacogenomic Literacy (MAPL™)

Technology Overview

Pharmacogenomic (PGx) testing is increasingly entering mainstream clinical practice and is of great interest to patients and providers. Research in disease risk genomics indicates that individuals with greater genomic knowledge are better equipped to make informed decisions about obtaining genetic testing, understanding the results, and taking appropriate action based upon the findings. However, studies examining components of PGx knowledge in patients have consistently identified areas of potential confusion or concern, and no PGx-specific validated literacy assessment has yet been developed.

In order to address this need, researchers at the University of Minnesota have developed the Minnesota Assessment of Pharmacogenomic Literacy (MAPL) assessment. MAPL is a validated questionnaire composed of 13 questions designed to assess the PGx knowledge of patients in four domains: underlying concepts, limitations, benefits, and privacy. Thus, MAPL represents a useful tool for clinical and research settings where quantitative assessment of PGx literacy is of value.

Now available in Chinese.

If you are interested in using this questionnaire for commercial applications, please contact us.

Researcher for Contact

• Jeffrey Bishop, PharmD, MS, BCPP, FCCP Associate Professor, Department of Experimental and Clinical Pharmacology (ECP)